This post was originally published on this site
(Reuters) – Britain’s GSK will limit the use of its ovarian cancer treatment Zejula in the United States, to patients with some particular mutations when being given as a second option to maintain their treatment, following a request from authorities.
The drugmaker said on Friday it would restrict the second-line maintenance indication for Zejula to only patients with harmful, or suspected to be harmful, inherited BRCA mutations, at the request of the U.S. Food and Drug Administration (FDA).
